Immunopathology Core

$130,473P01FY2005HLNIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 35967365 Paper 32938831 Paper 32713099 Paper 32087929 Paper 31811777 Paper 31561273 Paper 31335760 Paper 31292263 Paper 31170216 Paper 31027947 Paper 30516578 Paper 30380412 Paper 29988091 Paper 29939471 Paper 29873181 Paper 29661826 Paper 29505692 Paper 29434595 Paper 29377632 Paper 29300231 Paper 29288556 Paper 29286578 Paper 29189413 Paper 29187852 Paper 29175110 Paper 29173391 Paper 29055600 Paper 28930796 Paper 28826941 Paper 28551309 Paper 28459117 Paper 28444814 Paper 28306193 Paper 28302753 Paper 28293238 Paper 28258702 Paper 28049555 Paper 28018349 Paper 27942611 Paper 27863545 Paper 27695003 Paper 27446989 Paper 27196520 Paper 27017850 Paper 26671971 Paper 26643572 Paper 26516062 Paper 26469344 Paper 26337731 Paper 26310466 Paper 26190648 Paper 26147678 Paper 26039215 Paper 25958791 Paper 25904524 Paper 25824550 Paper 25772308 Paper 25757218 Paper 25757217 Paper 25563992 Paper 25563988 Paper 25559257 Paper 25394378 Paper 25321164 Paper 25155089 Paper 24926829 Paper 24789875 Paper 24517437 Paper 24517422 Paper 24304495 Paper 24165326 Paper 24033991 Paper 23656665 Paper 22682297 Paper 22627859 Paper 22586034 Paper 22053723 Paper 21957140 Paper 21831158 Paper 21653831 Paper 21601837 Paper 21512437 Paper 21157342 Paper 21116311 Paper 21116310 Paper 20729209 Paper 20642676 Paper 20605588 Paper 20590685 Paper 20486921 Paper 20071709 Paper 20055805 Paper 19542889 Paper 19424011 Paper 19273152 Paper 19249572 Paper 19202432 Paper 19145702 Paper 19134161 Paper 19017953

Abstract

The purpose of Core A is to provide common facilities and expertise for the immunopathological studies in all four projects of the Program Project. One might question the need for pathological analysis in a Program Project whose principal goal is the establishment of transplantation tolerance, since, if this goal were achieved, there would be little, if any graft pathology to analyze. However, it is clear that guidance from pathological analysis is essential to achieve our goal. The primary role of the pathological analyses in these tolerance protocols is to document and characterize: 1) The status of the graft (nature of infiltrate, presence of acute or chronic rejection, including humoral component) 2) The status of chimerism (cell type, distribution) 3) The systemic effects of the protocols (toxicity, complications). In addition, many valuable opportunities arise in the course of the proposed studies that will give insights into the mechanisms of graft rejection and acceptance. In particular, with protocol biopsies in the large animal studies we have the opportunity to: 4) Distinguish the nature of the infiltrate that leads to acceptance vs. rejection 5) Analyze grafts for precursor lesions that predict outcome, e.g., chronic rejection. The pathology features will be assessed and graded by the same group pathologists for all studies, which we consider an important asset of the Program Project. The panel of antibodies and cytokine probes will also be comparable, whenever possible. This should promote cross-fertilization among the projects by extension of novel findings and provide insights into the general significance of the results in one project by comparing and contrasting grafts in different species and between different organs. We also have a well annotated tissue bank of frozen and paraffin embedded tissue available from our previous transplantation experiments (>5000 samples), which can be drawn upon to expand and refine our analysis.

View original record on NIH RePORTER →